DK2327763T3 - Antigen generation af specifikke T-celler - Google Patents
Antigen generation af specifikke T-celler Download PDFInfo
- Publication number
- DK2327763T3 DK2327763T3 DK10179257.0T DK10179257T DK2327763T3 DK 2327763 T3 DK2327763 T3 DK 2327763T3 DK 10179257 T DK10179257 T DK 10179257T DK 2327763 T3 DK2327763 T3 DK 2327763T3
- Authority
- DK
- Denmark
- Prior art keywords
- cells
- hla
- cell
- antigen
- dcs
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 222
- 108091007433 antigens Proteins 0.000 title claims abstract description 93
- 102000036639 antigens Human genes 0.000 title claims abstract description 93
- 239000000427 antigen Substances 0.000 title claims abstract description 92
- 210000004027 cell Anatomy 0.000 claims abstract description 258
- 238000000034 method Methods 0.000 claims abstract description 56
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 230000009261 transgenic effect Effects 0.000 claims abstract description 13
- 210000004443 dendritic cell Anatomy 0.000 claims description 162
- 108091008874 T cell receptors Proteins 0.000 claims description 71
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 71
- 206010028980 Neoplasm Diseases 0.000 claims description 54
- 239000003446 ligand Substances 0.000 claims description 52
- 230000014509 gene expression Effects 0.000 claims description 40
- 210000004881 tumor cell Anatomy 0.000 claims description 31
- 210000004698 lymphocyte Anatomy 0.000 claims description 28
- 201000001441 melanoma Diseases 0.000 claims description 23
- 150000007523 nucleic acids Chemical class 0.000 claims description 20
- 108020004707 nucleic acids Proteins 0.000 claims description 19
- 102000039446 nucleic acids Human genes 0.000 claims description 19
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 17
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 claims description 12
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 11
- 239000013598 vector Substances 0.000 claims description 8
- 210000000265 leukocyte Anatomy 0.000 claims description 7
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 claims description 5
- 238000010367 cloning Methods 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 claims description 4
- 108700019146 Transgenes Proteins 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 238000001802 infusion Methods 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 108010062347 HLA-DQ Antigens Proteins 0.000 claims description 3
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 3
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 201000008275 breast carcinoma Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 201000005296 lung carcinoma Diseases 0.000 claims description 3
- 201000003866 lung sarcoma Diseases 0.000 claims description 3
- 201000001514 prostate carcinoma Diseases 0.000 claims description 3
- 229960005486 vaccine Drugs 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 2
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 55
- 230000000735 allogeneic effect Effects 0.000 abstract description 32
- 238000011467 adoptive cell therapy Methods 0.000 abstract description 12
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 120
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 117
- 102000003425 Tyrosinase Human genes 0.000 description 64
- 108060008724 Tyrosinase Proteins 0.000 description 64
- 210000000612 antigen-presenting cell Anatomy 0.000 description 40
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 38
- 238000000338 in vitro Methods 0.000 description 30
- 108090000623 proteins and genes Proteins 0.000 description 29
- 108010074328 Interferon-gamma Proteins 0.000 description 27
- 102000004127 Cytokines Human genes 0.000 description 26
- 108090000695 Cytokines Proteins 0.000 description 26
- 102100037850 Interferon gamma Human genes 0.000 description 26
- 238000004520 electroporation Methods 0.000 description 25
- 102000004169 proteins and genes Human genes 0.000 description 25
- 238000010186 staining Methods 0.000 description 25
- 239000002609 medium Substances 0.000 description 24
- 241000282414 Homo sapiens Species 0.000 description 23
- 230000037452 priming Effects 0.000 description 22
- 108091054437 MHC class I family Proteins 0.000 description 21
- 238000011534 incubation Methods 0.000 description 21
- 102000004196 processed proteins & peptides Human genes 0.000 description 21
- 238000012546 transfer Methods 0.000 description 21
- 239000000872 buffer Substances 0.000 description 19
- 229960003130 interferon gamma Drugs 0.000 description 18
- 230000027455 binding Effects 0.000 description 16
- 241000894006 Bacteria Species 0.000 description 15
- 102000043129 MHC class I family Human genes 0.000 description 15
- 108020004999 messenger RNA Proteins 0.000 description 15
- 238000000684 flow cytometry Methods 0.000 description 14
- 239000013612 plasmid Substances 0.000 description 14
- 239000000725 suspension Substances 0.000 description 13
- 239000012636 effector Substances 0.000 description 12
- 210000001616 monocyte Anatomy 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 230000028327 secretion Effects 0.000 description 11
- 230000004936 stimulating effect Effects 0.000 description 11
- 238000013518 transcription Methods 0.000 description 11
- 230000035897 transcription Effects 0.000 description 11
- 230000006870 function Effects 0.000 description 10
- 230000000638 stimulation Effects 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 9
- 102000004388 Interleukin-4 Human genes 0.000 description 9
- 108090000978 Interleukin-4 Proteins 0.000 description 9
- 229940028885 interleukin-4 Drugs 0.000 description 9
- 238000011476 stem cell transplantation Methods 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 230000035800 maturation Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 8
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 8
- 229930182490 saponin Natural products 0.000 description 8
- 150000007949 saponins Chemical class 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 7
- 108010002350 Interleukin-2 Proteins 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000003834 intracellular effect Effects 0.000 description 7
- 208000009329 Graft vs Host Disease Diseases 0.000 description 6
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 6
- 108010004729 Phycoerythrin Proteins 0.000 description 6
- 239000012980 RPMI-1640 medium Substances 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 208000024908 graft versus host disease Diseases 0.000 description 6
- 208000032839 leukemia Diseases 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000008030 elimination Effects 0.000 description 5
- 238000003379 elimination reaction Methods 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000011148 porous material Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 4
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 4
- 102000019034 Chemokines Human genes 0.000 description 4
- 108010012236 Chemokines Proteins 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 108010002586 Interleukin-7 Proteins 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 102100022748 Wilms tumor protein Human genes 0.000 description 4
- 230000004186 co-expression Effects 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 229940029030 dendritic cell vaccine Drugs 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 210000002752 melanocyte Anatomy 0.000 description 4
- 210000003289 regulatory T cell Anatomy 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
- 210000001541 thymus gland Anatomy 0.000 description 4
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 3
- 108090000172 Interleukin-15 Proteins 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 108091054438 MHC class II family Proteins 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 108091036407 Polyadenylation Proteins 0.000 description 3
- 230000037453 T cell priming Effects 0.000 description 3
- 230000000961 alloantigen Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000005809 anti-tumor immunity Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000005784 autoimmunity Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000000139 costimulatory effect Effects 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 238000002825 functional assay Methods 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 101100400999 Caenorhabditis elegans mel-28 gene Proteins 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 238000007400 DNA extraction Methods 0.000 description 2
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 2
- 108010010378 HLA-DP Antigens Proteins 0.000 description 2
- 102000015789 HLA-DP Antigens Human genes 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- 101000621309 Homo sapiens Wilms tumor protein Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 description 2
- 206010047642 Vitiligo Diseases 0.000 description 2
- 108700020467 WT1 Proteins 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000009172 cell transfer therapy Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 230000005684 electric field Effects 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000010212 intracellular staining Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002250 progressing effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 229940054269 sodium pyruvate Drugs 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000003970 toll like receptor agonist Substances 0.000 description 2
- 108010055094 transporter associated with antigen processing (TAP) Proteins 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- BRZYSWJRSDMWLG-DJWUNRQOSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-[(1r)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-DJWUNRQOSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- RNAMYOYQYRYFQY-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound N1=C(N2CCC(F)(F)CC2)N=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1CCN(C(C)C)CC1 RNAMYOYQYRYFQY-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 108010068307 Alpha-Globulins Proteins 0.000 description 1
- 235000010585 Ammi visnaga Nutrition 0.000 description 1
- 244000153158 Ammi visnaga Species 0.000 description 1
- 102100030346 Antigen peptide transporter 1 Human genes 0.000 description 1
- 102100030343 Antigen peptide transporter 2 Human genes 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 241000710829 Dengue virus group Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 1
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 1
- 102100028970 HLA class I histocompatibility antigen, alpha chain E Human genes 0.000 description 1
- 102000011786 HLA-A Antigens Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 description 1
- 108010058607 HLA-B Antigens Proteins 0.000 description 1
- 108010091938 HLA-B7 Antigen Proteins 0.000 description 1
- 108010052199 HLA-C Antigens Proteins 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000986085 Homo sapiens HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 108010023335 Member 2 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 101150076359 Mhc gene Proteins 0.000 description 1
- 239000012570 Opti-MEM I medium Substances 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 238000006527 Schoenberg reaction Methods 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 101800000849 Tachykinin-associated peptide 2 Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000003012 bilayer membrane Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011246 intracellular protein detection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000034701 macropinocytosis Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000001400 myeloablative effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 102000044158 nucleic acid binding protein Human genes 0.000 description 1
- 108700020942 nucleic acid binding protein Proteins 0.000 description 1
- 238000013021 overheating Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- AYEKOFBPNLCAJY-UHFFFAOYSA-O thiamine pyrophosphate Chemical compound CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N AYEKOFBPNLCAJY-UHFFFAOYSA-O 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464456—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Claims (7)
- Titel Antigen generation af specifikke T-celler1. En allo-begrænset antigen specifik human CD4+ T-celle, der er tilgængelig vha. en metode der består af følgende trin: a) tilvejebringelse af en nukleinsyre kodning for et patientafledt MHC klasse II molekyle og et antigen eller en nukleinsyre kodning for antigenet, hvor antigenet er valgt fra et fast tumorcelleassocieret antigen; b) co-transfektion eller indføring af begge forbindelser som defineret i a) i dendritiske celler afledt fra en sund donor, fortrinsvis fra modne dendritiske celler; c) klargøring af perifere lymfocytter (PBL'er), som er autologe i lyset af APC'erne og som stammer fra den sunde donor med APC'erne; d) udvælgelse af humane CD4 + T-celler, som er specifikke for MHC-antigenliganden til anvendelse i en fremgangsmåde til behandling af faste tumorer.
- 2. Den allo-begrænsede antigenspecifikke humane CD4 + T-celle til anvendelse ifølge krav 1, hvor det tumorassocierede antigen stammer fra faste tumorer, primært colonkarcinom, brystkarcinom, prostatakarcinom, renalcellekarcinom (RCC), lungekarcinom, sarkom eller melanomceller.
- 3. Den allo-begrænsede antigenspecifikke humane CD4 + T-celle til anvendelse på et af de to krav 1-2, hvor fremgangsmåden yderligere omfatter trin e) kloning af T-celle-receptoren (TCR) af de isolerede CD4+ T-celler, og eventuelt omfatter trin f) ekspression af TCR transgenerne i PBMC.
- 4. Den allo-begrænsede antigenspecifikke humane CD4 + T-celle til anvendelse på et af de foregående krav, hvor MHC-molekylet er valgt blandt HLADP, HLA-DQ eller HLA-DR.
- 5. En PBMC, som er blevet transformeret med en vektor omfattende en nukleinsyre, der koder for en transgen TCR, tilgængelig med fremgangsmåden trin a) til d) ifølge krav 1 og e) og eventuelt f) ifølge krav 3 til anvendelse i en fremgangsmåde til behandling af faste tumorer.
- 6. En farmaceutisk sammensætning, som omfatter CD4 + T-celler ifølge et af krav 1-4 eller PBMC ifølge krav 5 og en farmaceutisk acceptabel bærer til anvendelse i en fremgangsmåde til behandling af faste tumorer.
- 7. Den farmaceutiske sammensætning til anvendelse ifølge krav 6, som er en infusion, injektion eller en vaccine.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05017128 | 2005-08-05 | ||
| EP06007539 | 2006-04-10 | ||
| EP06776623A EP1910521B1 (en) | 2005-08-05 | 2006-08-04 | Generation of allorestricted antigen specific t cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2327763T3 true DK2327763T3 (da) | 2018-05-22 |
Family
ID=37598202
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10179257.0T DK2327763T3 (da) | 2005-08-05 | 2006-08-04 | Antigen generation af specifikke T-celler |
| DK06776623.8T DK1910521T3 (da) | 2005-08-05 | 2006-08-04 | Generering af allo-begrænsede, antigenspecifikke T-celler |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK06776623.8T DK1910521T3 (da) | 2005-08-05 | 2006-08-04 | Generering af allo-begrænsede, antigenspecifikke T-celler |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8486694B2 (da) |
| EP (3) | EP3369812B1 (da) |
| JP (3) | JP5079697B2 (da) |
| AT (1) | ATE484578T1 (da) |
| DE (1) | DE602006017556D1 (da) |
| DK (2) | DK2327763T3 (da) |
| ES (2) | ES2672895T3 (da) |
| HU (1) | HUE038833T2 (da) |
| PL (1) | PL2327763T3 (da) |
| PT (1) | PT2327763T (da) |
| WO (1) | WO2007017201A1 (da) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10112851C1 (de) * | 2001-03-16 | 2002-10-10 | Gsf Forschungszentrum Umwelt | Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen |
| WO2006036445A2 (en) | 2004-09-24 | 2006-04-06 | Trustees Of Dartmouth College | Chimeric nk receptor and methods for treating cancer |
| HUE038833T2 (hu) * | 2005-08-05 | 2018-11-28 | Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh | Antigénspecifikus T-sejtek létrehozása |
| EP2098536A1 (en) | 2008-03-05 | 2009-09-09 | 4-Antibody AG | Isolation and identification of antigen- or ligand-specific binding proteins |
| CA2743669C (en) | 2008-11-24 | 2018-10-16 | Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) | High affinity t cell receptor and use thereof |
| EP2393833A1 (en) * | 2009-02-09 | 2011-12-14 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Repertoire of allo-restricted peptide-specific t cell receptor sequences and use thereof |
| US9273283B2 (en) | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
| WO2011059836A2 (en) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
| DK2618835T3 (da) * | 2010-09-20 | 2017-08-28 | Biontech Cell & Gene Therapies Gmbh | Antigen-specifikke t-cellereceptorer og t-celleepitoper |
| WO2013033626A2 (en) | 2011-08-31 | 2013-03-07 | Trustees Of Dartmouth College | Nkp30 receptor targeted therapeutics |
| EP3766896A1 (en) * | 2011-09-15 | 2021-01-20 | The United States of America, as represented by The Secretary, Department of Health and Human Services | T cell receptors recognizing hla-a1- or hla-cw7-restricted mage |
| ES2719495T3 (es) | 2012-05-07 | 2019-07-10 | Dartmouth College | Anticuerpo dirigido contra b7-h6, proteínas de fusión, y métodos de uso de los mismos |
| EP2859093A4 (en) * | 2012-06-11 | 2016-08-17 | Wolf Wilson Mfg Corp | IMPROVED METHODS FOR CELL CULTURES FOR ADOPTIVE CELL THERAPIES |
| AU2013308409A1 (en) | 2012-08-31 | 2015-03-26 | University Of Birmingham | Target peptides for immunotherapy and diagnostics |
| EP4088737A3 (en) | 2012-09-05 | 2023-02-08 | University Of Virginia Patent Foundation | Target peptides for colorectal cancer therapy and diagnostics |
| GB2508414A (en) * | 2012-11-30 | 2014-06-04 | Max Delbrueck Centrum | Tumour specific T cell receptors (TCRs) |
| AU2014351871B2 (en) | 2013-11-22 | 2020-02-13 | Cellectis | Method for generating batches of allogeneic T-cells with averaged potency |
| US20170081635A1 (en) * | 2014-03-20 | 2017-03-23 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Tumor-infiltrating lymphocytes for adoptive cell therapy |
| AU2015247727A1 (en) * | 2014-04-15 | 2016-11-03 | University Of Virginia Patent Foundation | Isolated T cell receptors and methods of use therefor |
| CN107075479A (zh) | 2014-10-02 | 2017-08-18 | 美国卫生和人力服务部 | 分离对癌症特异性突变具有抗原特异性的t细胞的方法 |
| EP4074333A1 (en) * | 2014-10-02 | 2022-10-19 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Methods of isolating t cell receptors having antigenic specificity for a cancer-specific mutation |
| EP3215164A1 (en) | 2014-11-03 | 2017-09-13 | Immures S.r.l. | T cell receptors |
| US20170333480A1 (en) * | 2014-11-05 | 2017-11-23 | Board Of Regents, The University Of Texas System | Gene modified immune effector cells and engineered cells for expansion of immune effector cells |
| WO2016085904A1 (en) * | 2014-11-26 | 2016-06-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mutated kras t cell receptors |
| WO2016146618A1 (en) | 2015-03-16 | 2016-09-22 | Max-Delbrück-Centrum für Molekulare Medizin | Method of detecting new immunogenic t cell epitopes and isolating new antigen-specific t cell receptors by means of an mhc cell library |
| CN107922950B (zh) | 2015-06-01 | 2021-12-31 | 基因医疗免疫疗法有限责任公司 | T细胞受体文库 |
| NZ737423A (en) | 2015-06-01 | 2019-08-30 | Medigene Immunotherapies Gmbh | Method for generating antibodies against t cell receptor |
| US20170119820A1 (en) | 2015-07-31 | 2017-05-04 | Regents Of The University Of Minnesota | Modified cells and methods of therapy |
| SG10201913868XA (en) * | 2015-09-15 | 2020-03-30 | The United States Of America As Represented By The Secretary | T cell receptors recognizing hla-cw8 restricted mutated kras |
| GB201520550D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| EA201891459A1 (ru) | 2015-12-23 | 2018-11-30 | Медиджин Иммьюнотерапиз Гмбх | Новое поколение антигенспецифических tcr |
| ES2964746T3 (es) * | 2015-12-30 | 2024-04-09 | Celgene Corp | Métodos de producción de linfocitos T y linfocitos T producidos mediante el mismo |
| MA45491A (fr) * | 2016-06-27 | 2019-05-01 | Juno Therapeutics Inc | Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés |
| CN109996868A (zh) * | 2016-09-23 | 2019-07-09 | 弗雷德哈钦森癌症研究中心 | 特异性用于次要组织相容性(h)抗原ha-1的tcr及其用途 |
| CN110520530A (zh) | 2016-10-18 | 2019-11-29 | 明尼苏达大学董事会 | 肿瘤浸润性淋巴细胞和治疗方法 |
| WO2019006418A2 (en) | 2017-06-30 | 2019-01-03 | Intima Bioscience, Inc. | ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY |
| JP7181517B2 (ja) * | 2018-01-23 | 2022-12-01 | 国立大学法人三重大学 | Ｔ細胞レセプター |
| AU2019225798B2 (en) | 2018-02-26 | 2023-05-18 | Medigene Immunotherapies Gmbh | Nyeso tcr |
| WO2020055931A1 (en) * | 2018-09-10 | 2020-03-19 | Torque Therapeutics, Inc. | Antigen-specific t lymphocytes and methods of making and using the same |
| SG11202102878TA (en) * | 2018-09-27 | 2021-04-29 | Genocea Biosciences Inc | Treatment methods |
| CN113454208A (zh) * | 2018-12-12 | 2021-09-28 | 布里格姆及妇女医院股份有限公司 | 用于免疫抑制的组合物和方法 |
| EP3947435A1 (en) | 2019-04-04 | 2022-02-09 | Medigene Immunotherapies GmbH | Magea1 specific t cell receptors and their use |
| JP6878544B2 (ja) * | 2019-10-02 | 2021-05-26 | アメリカ合衆国 | がん特異的突然変異に対し抗原特異性を有するｔ細胞を単離する方法 |
| JP7340144B2 (ja) * | 2019-10-02 | 2023-09-07 | アメリカ合衆国 | がん特異的突然変異に対し抗原特異性を有するｔ細胞を単離する方法 |
| EP4126962A1 (en) | 2020-04-01 | 2023-02-08 | Medigene Immunotherapies GmbH | Cd3-fusion protein and uses thereof |
| JP2020143057A (ja) * | 2020-04-01 | 2020-09-10 | アメリカ合衆国 | がん特異的突然変異に対し抗原特異性を有するｔ細胞受容体を単離する方法 |
| US20230287345A1 (en) | 2020-08-18 | 2023-09-14 | Medigene Immunotherapies Gmbh | ENRICHMENT OF T CELLS USING AN ANTI-Cß ANTIBODY |
| BR112023005318A2 (pt) | 2020-09-24 | 2023-04-25 | Medigene Immunotherapies Gmbh | Receptores de célula t específicos de prame e uso dos mesmos |
| WO2023175069A1 (en) | 2022-03-16 | 2023-09-21 | Medigene Immunotherapies Gmbh | Tcr constant region pairing library for pramevld tcrs |
| WO2023175070A1 (en) | 2022-03-16 | 2023-09-21 | Medigene Immunotherapies Gmbh | Tcr constant region pairing library |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997026328A1 (en) * | 1996-01-17 | 1997-07-24 | Imperial College Innovations Limited | Immunotherapy using cytotoxic t lymphocytes (ctl) |
| ATE328279T1 (de) * | 2002-08-23 | 2006-06-15 | Deutsches Rheuma Forschungszen | Verfahren zum nachweis und zur isolierung von t- lymphozyten, die ein definiertes antigen erkennen |
| HUE038833T2 (hu) * | 2005-08-05 | 2018-11-28 | Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh | Antigénspecifikus T-sejtek létrehozása |
-
2006
- 2006-08-04 HU HUE10179257A patent/HUE038833T2/hu unknown
- 2006-08-04 EP EP18161391.0A patent/EP3369812B1/en active Active
- 2006-08-04 DK DK10179257.0T patent/DK2327763T3/da active
- 2006-08-04 EP EP06776623A patent/EP1910521B1/en active Active
- 2006-08-04 PL PL10179257T patent/PL2327763T3/pl unknown
- 2006-08-04 ES ES10179257T patent/ES2672895T3/es active Active
- 2006-08-04 DK DK06776623.8T patent/DK1910521T3/da active
- 2006-08-04 PT PT101792570T patent/PT2327763T/pt unknown
- 2006-08-04 US US11/990,054 patent/US8486694B2/en active Active
- 2006-08-04 ES ES18161391T patent/ES2842878T3/es active Active
- 2006-08-04 JP JP2008524450A patent/JP5079697B2/ja active Active
- 2006-08-04 DE DE602006017556T patent/DE602006017556D1/de active Active
- 2006-08-04 EP EP10179257.0A patent/EP2327763B1/en active Active
- 2006-08-04 AT AT06776623T patent/ATE484578T1/de active
- 2006-08-04 WO PCT/EP2006/007752 patent/WO2007017201A1/en active Application Filing
-
2012
- 2012-07-10 JP JP2012154420A patent/JP2012213402A/ja active Pending
-
2013
- 2013-07-12 US US13/940,715 patent/US20140141026A1/en not_active Abandoned
-
2016
- 2016-02-05 JP JP2016020781A patent/JP2016135127A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DE602006017556D1 (de) | 2010-11-25 |
| ATE484578T1 (de) | 2010-10-15 |
| WO2007017201A1 (en) | 2007-02-15 |
| HUE038833T2 (hu) | 2018-11-28 |
| DK1910521T3 (da) | 2011-02-07 |
| EP1910521A1 (en) | 2008-04-16 |
| ES2672895T3 (es) | 2018-06-18 |
| JP2016135127A (ja) | 2016-07-28 |
| PT2327763T (pt) | 2018-05-11 |
| PL2327763T3 (pl) | 2018-08-31 |
| ES2842878T3 (es) | 2021-07-15 |
| EP2327763B1 (en) | 2018-03-14 |
| EP3369812B1 (en) | 2020-10-07 |
| EP3369812A1 (en) | 2018-09-05 |
| JP2012213402A (ja) | 2012-11-08 |
| EP2327763A1 (en) | 2011-06-01 |
| JP5079697B2 (ja) | 2012-11-21 |
| US20100189728A1 (en) | 2010-07-29 |
| JP2009502185A (ja) | 2009-01-29 |
| US8486694B2 (en) | 2013-07-16 |
| US20140141026A1 (en) | 2014-05-22 |
| EP1910521B1 (en) | 2010-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2327763T3 (da) | Antigen generation af specifikke T-celler | |
| EP2700708B1 (en) | Enhancing the T-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination | |
| CN114836385A (zh) | 改变cart细胞中的基因表达及其用途 | |
| JP2022065022A (ja) | 改変ヒト初代血液樹状細胞株を生成するための方法 | |
| US11684671B2 (en) | Enhancing the T-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination | |
| WO1995004817A1 (en) | Methods for ex vivo therapy using peptide-loaded antigen presenting cells for the activation of ctl | |
| AU2006323961A1 (en) | Methods for generating antigen-specific effector T cells | |
| EP3730515B1 (en) | A fully-human t cell receptor specific for the 369-377 epitope derived from the her2/neu (erbb2) receptor protein | |
| US8323965B2 (en) | Identification of antigenic peptides from multiple myeloma cells | |
| Toujas et al. | Human monocyte‐derived macrophages and dendritic cells are comparably effective in vitro in presenting HLA class I‐restricted exogenous peptides | |
| JP4435985B2 (ja) | ＴｃＲγδＴ細胞の生産方法 | |
| Inzkirweli et al. | Antigen loading of dendritic cells with apoptotic tumor cell-preparations is superior to that using necrotic cells or tumor lysates | |
| Hsu et al. | RNA Loading of Leukemic Antigens into Cord Blood–Derived Dendritic Cells for Immunotherapy | |
| EP3173474A1 (en) | Enhancing the t-cells stimulatory capacity of human antigen presenting cells and their use in vaccination | |
| KR20210024038A (ko) | 치료용 수지상 세포의 시험관내 분화 및 성숙 방법 | |
| JP7572700B2 (ja) | 改変ヒト初代血液樹状細胞株を生成するための方法 | |
| WO2020223821A1 (en) | Miha peptide combinations and uses thereof | |
| JP2018531022A6 (ja) | 改変ヒト初代血液樹状細胞株を生成するための方法 | |
| Tiurbe | Characterization of immature rat bone marrow-derived dendritic cells: Evaluation of their phenotype and immunomodulatory properties in vitro and after organ transplantation | |
| Tiurbe | Charakterisierung unreifer dendritischer Zellen aus dem Knochenmark der Ratte: Untersuchungen zum Phänotyp und zur Immunmodulation in vitro und nach Organtransplantation |